




Searching News Database: pirfenidone
HSMN NewsFeed - 28 Jan 2019
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
HSMN NewsFeed - 25 Feb 2014
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
HSMN NewsFeed - 27 Mar 2012
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
HSMN NewsFeed - 2 Mar 2010
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
HSMN NewsFeed - 5 Nov 2009
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
HSMN NewsFeed - 19 May 2008
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
HSMN NewsFeed - 18 Mar 2008
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
HSMN NewsFeed - 5 Mar 2007
InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
HSMN NewsFeed - 27 Apr 2006
InterMune Initiates Phase III Program Evaluating Pirfenidone in Patients With IPF
InterMune Initiates Phase III Program Evaluating Pirfenidone in Patients With IPF
HSMN NewsFeed - 3 Jan 2006
InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash
InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash
Additional items found! 18

Members Archive contains
18 additional stories matching:
pirfenidone
(Password required)
pirfenidone
(Password required)